1)日本胃癌学会(編).薬物療法・放射線療法.胃癌取扱い規約,13版.pp 18-21,金原出版,1999
2)栗原稔,江口研二,下妻晃二郎,他.がん薬物療法におけるQOL調査表.日癌治 28 : 1140-1144, 1993
3)Kurihara M, Shimizu H, Tsuboi K, et al. Development of quality of life questionnaire in Japan : Quality of life assessment of cancer patients receiving chemotherapy. Psychooncology 8 : 355-363, 1999
4)ICH Harmonized Tripartite Guideline Statistical Principles for Clinical Trials, Full Analysis Set,(5 Feb), pp 5, 21-22, 1988(日本語訳厚生省医薬審第1047号(10.11.30)
5)Therasse P, Arbuck G, Eisenhauer A, et al. New guideline to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 : 205-216, 2000
6)WHO handbook for reporting results of cancer treatment. Geneva(Switzerland): World Health Organization Offset Publication No.48, 1979
7)Koizumi W, Kurihara M, Tanabe S, et al. Advantage of Japanese Response criteria for estimating the survival of patients with primary advanced gastric cancer. Gastric Cancer 2 : 14-19, 1999
8)Yoshida S, Miyata Y, Ohtsu A, et al. Significance of and problems on adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer. Gastric Cancer 3 : 128-133, 2000
9)Kiyohashi A, Kurihara M, Yoshida S, et al. Antitumor effect and survival benefit of chemotherapy for unresectable advanced gastric cancer. Jpn J Clin Oncol 23 : 41-45, 1993
10)Ohtsu A, Boku N, Yoshida S, et al. Response of the primary lesion in gastric cancer to chemotherapeutic trials. Int J Clin Oncol 3 : 3-6, 1998
11)小泉和三郎,田辺聡,西元寺克禮,他.進行胃癌化学療法評価におけるRECISTの問題点.日本癌治療学会総会(仙台).日癌治抄録集,2000